VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
201
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $204K | 0.08% |
5,171
-3,872
| -43% | -$153K |
|
202
Relmada Therapeutics
RLMD
$54.8M
| $203K | 0.08% |
9,015
+2,312
| +34% | +$52.1K |
|
203
Axsome Therapeutics
AXSM
$6.25B
| $202K | 0.08% |
5,350
+2,204
| +70% | +$83.2K |
|
204
Cytokinetics
CYTK
$6.34B
| $202K | 0.08% |
4,425
-5,298
| -54% | -$242K |
|
205
Syndax Pharmaceuticals
SNDX
$1.47B
| $202K | 0.08% |
9,238
-2,003
| -18% | -$43.8K |
|
206
Adicet Bio
ACET
$60M
| $201K | 0.08% |
+11,511
| New | +$201K |
|
207
Oric Pharmaceuticals
ORIC
$1.06B
| $201K | 0.08% |
13,677
+2,895
| +27% | +$42.5K |
|
208
Xenon Pharmaceuticals
XENE
$3.02B
| $201K | 0.08% |
6,439
-5,055
| -44% | -$158K |
|
209
Keros Therapeutics
KROS
$633M
| $200K | 0.08% |
3,416
-600
| -15% | -$35.1K |
|
210
TG Therapeutics
TGTX
$5.11B
| $200K | 0.08% |
10,536
+4,987
| +90% | +$94.7K |
|
211
RAPT Therapeutics
RAPT
$214M
| $198K | 0.07% |
674
+10
| +2% | +$2.94K |
|
212
Roivant Sciences
ROIV
$8.82B
| $198K | 0.07% |
+19,648
| New | +$198K |
|
213
Nkarta
NKTX
$161M
| $197K | 0.07% |
12,843
+4,922
| +62% | +$75.5K |
|
|
LENZ
214
LENZ Therapeutics
LENZ
$1.2B
| $197K | 0.07% |
+2,265
| New | +$197K |
|
|
TPTX
215
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $197K | 0.07% |
4,131
+1,396
| +51% | +$66.6K |
|
216
Kymera Therapeutics
KYMR
$3.11B
| $195K | 0.07% |
3,071
-1,134
| -27% | -$72K |
|
217
Xencor
XNCR
$610M
| $195K | 0.07% |
4,869
-822
| -14% | -$32.9K |
|
|
IMGN
218
DELISTED
Immunogen Inc
IMGN
| $195K | 0.07% |
26,323
-5,929
| -18% | -$43.9K |
|
219
ESSA Pharma
EPIX
$11M
| $194K | 0.07% |
13,643
+5,817
| +74% | +$82.7K |
|
220
Zentalis Pharmaceuticals
ZNTL
$126M
| $194K | 0.07% |
2,305
-1,489
| -39% | -$125K |
|
|
BCYC
221
Bicycle Therapeutics
BCYC
$496M
| $193K | 0.07% |
3,166
-3,964
| -56% | -$242K |
|
222
Prothena Corp
PRTA
$460M
| $193K | 0.07% |
3,901
-557
| -12% | -$27.6K |
|
223
Fate Therapeutics
FATE
$116M
| $192K | 0.07% |
3,274
+918
| +39% | +$53.8K |
|
224
Madrigal Pharmaceuticals
MDGL
$9.65B
| $192K | 0.07% |
2,270
+294
| +15% | +$24.9K |
|
225
Crinetics Pharmaceuticals
CRNX
$3.35B
| $191K | 0.07% |
6,726
-4,499
| -40% | -$128K |
|